Cancer Cachexia Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
DelveInsight’s, “Cancer Cachexia Pipeline Insight 2023” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cancer Cachexia pipeline landscape. It covers the Cancer Cachexia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cancer Cachexia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cancer Cachexia Pipeline Report
- DelveInsight’s Cancer Cachexia pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Cancer Cachexia treatment.
- The leading companies working in the Cancer Cachexia Market include AEterna Zentaris, Pfizer, Incyte Corporation, Smartfish AS, NGM Biopharmaceuticals, Caelus Health, Helsinn Therapeutics/Ono Pharmaceutical, Aphios Corporation, Actimed Therapeutics, Ildong Pharmaceutical, Tetra Biopharma, Aveo Oncology, and others.
- Promising Cancer Cachexia Pipeline Therapies in the various stages of development include MT-102, Eicosapentaenoic Acid, Lenalidomide, OC514 (Low dose), RC-1291, and others.
- November 2023: Tu Dan announced a study of Early Phase 1 clinical trials for Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.
- November 2023: Pfizer announced a study of Phase 2 clinical trials for Ponsegromab. Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
Request a sample and discover the recent advances in Cancer Cachexia Treatment Drugs @ Cancer Cachexia Pipeline Report
In the Cancer Cachexia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cancer Cachexia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Cancer Cachexia Overview
Cancer cachexia is a wasting syndrome characterized by weight loss, anorexia, asthenia and anemia. The pathogenicity of this syndrome is multifactorial, due to a complex interaction of tumor and host factors. The signs and symptoms of cachexia are considered as the prognostic parameters in cancer patients. Cancer cachexia most often affects patients with cancers of the upper gastrointestinal tract, including the esophagus, stomach, and pancreas. Not all cancer patients are affected equally by cachexia.
Find out more about Cancer Cachexia Therapeutics Assessment @ Cancer Cachexia Preclinical and Discovery Stage Products
Cancer Cachexia Emerging Drugs Profile
- Macimorelin: AEterna Zentaris
- PF- 06946860: Pfizer
Cancer Cachexia Pipeline Therapeutics Assessment
There are approx. 15+ key companies which are developing the therapies for Cancer Cachexia. The Cancer Cachexia companies which have their Cancer Cachexia drug candidates in the most advanced stage, i.e. Phase II include, AEterna Zentaris.
DelveInsight’s Cancer Cachexia Pipeline Report covers around 15+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Cancer Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
Cancer Cachexia Pipeline Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Learn more about the emerging Cancer Cachexia Pipeline Therapies @ Cancer Cachexia Clinical Trials Assessment
Scope of the Cancer Cachexia Pipeline Report
- Coverage- Global
- Cancer Cachexia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Cancer Cachexia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Cancer Cachexia Companies- AEterna Zentaris, Pfizer, Incyte Corporation, Smartfish AS, NGM Biopharmaceuticals, Caelus Health, Helsinn Therapeutics/Ono Pharmaceutical, Aphios Corporation, Actimed Therapeutics, Ildong Pharmaceutical, Tetra Biopharma, Aveo Oncology, and others.
- Cancer Cachexia Pipeline Therapies- MT-102, Eicosapentaenoic Acid, Lenalidomide, OC514 (Low dose), RC-1291, and others.
Dive deep into rich insights for new drugs for Cancer Cachexia Treatment, Visit @ Cancer Cachexia Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Cancer Cachexia: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- Macimorelin: AEterna Zentaris
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Early stage products (Phase I)
- PF- 06946860: Pfizer
- Drug profiles in the detailed report…..
- Inactive Products
- Cancer Cachexia Key Companies
- Cancer Cachexia Key Products
- Cancer Cachexia- Unmet Needs
- Cancer Cachexia- Market Drivers and Barriers
- Cancer Cachexia- Future Perspectives and Conclusion
- Cancer Cachexia Analyst Views
- Cancer Cachexia Key Companies
- Appendix
For further information on the Cancer Cachexia Pipeline therapeutics, reach out to Cancer Cachexia Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/major-depressive-disorder-market
){kind=link}